Top Brands for Cialis and ED Solutions

When it comes to addressing erectile dysfunction, Cialis, with its active ingredient tadalafil, has been a trusted option for many. This popular medication is known for offering longer-lasting effects compared to its counterparts, giving users more flexibility. Among the various brands that manufacture Cialis, a few have stood out due to their consistent quality, efficacy, and overall customer satisfaction. Below, we provide an insightful list of these top brands to guide your next purchase.

Illustration of cialis

Best brands of cialis in 2025

Lilly

Eli Lilly and Company has established itself as a leading producer of Cialis (tadalafil), a highly successful treatment for erectile dysfunction. Since its launch, Cialis has achieved significant milestones, including reaching $1 billion in global sales just over two years after its European debut. By 2006, Cialis held 35.5% of the global market share, gaining ground on Viagra's 49.3% share. In some countries, Cialis has even surpassed Viagra, holding up to 40% market share. The drug's popularity is attributed to its durability and effectiveness, making it a top choice in 17 countries.

Cipla

Cipla, although not the original producer of Cialis, is a significant player in the pharmaceutical industry and has a strong presence in the market, but it does not specifically produce Cialis. Cialis is manufactured by Lilly ICOS LLC, and it has gained substantial market share since its introduction, capturing up to 39% of the market in some regions and 15.7% of total oral ED prescriptions in the U.S. as of 2004. Cipla, however, has its own robust portfolio and financial performance, with net sales of Rs 14,441.14 crore in March 2024 and a strong presence in the global market. For more details about Cialis's market performance, visit the Lilly ICOS official release.

Teva Pharmaceuticals

Teva Pharmaceuticals is a leading global pharmaceutical company, renowned for its extensive portfolio of generic medicines, including the exclusive first-to-file launch of a generic version of Cialis (tadalafil) in the United States. This launch, announced in 2018, marked a significant milestone, given that Cialis had annual sales of nearly $1.93 billion in the U.S. as of July 2018. Tadalafil tablets, available in strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg, are indicated for the treatment of erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and both ED and BPH. Teva's generics business has consistently shown strong growth, with a 30% increase in the U.S. segment in the third quarter of 2024 compared to the previous year. As the largest generic drug manufacturer in the world, Teva holds a dominant position in the market, with over 550 generic medicines available.

Sandoz

Sandoz, formerly a division of Novartis, is a leading producer of generic medications, including Tadalafil Sandoz, a generic version of Cialis. In 2023, Sandoz reported net sales of $9.6 billion, with a 7% increase in constant currencies, driven by strong demand and product launches such as Omnitrope(r) and Hyrimoz(r). The company's generics segment, which includes Tadalafil Sandoz, saw a 5% growth in constant currencies, contributing significantly to the overall performance. Tadalafil Sandoz is used to treat erectile dysfunction and urinary symptoms associated with benign prostatic hyperplasia, with various dosages available, including 5 mg, 10 mg, and 20 mg tablets. As an independent company since 2023, Sandoz continues to expand its market presence in generic and biosimilar medicines.

Lupin Pharmaceuticals

Lupin Pharmaceuticals has established itself as a significant player in the erectile dysfunction market through its partnership with Eli Lilly to commercialize and distribute Cialis (tadalafil) in India. This collaboration allows Lupin to market, promote, and distribute Cialis, which holds around 23% of the Indian PDE-5 market valued at INR 390 crore. The market has seen substantial growth, doubling since 2012 and expanding at an annual rate of 15%. Lupin's generic version of tadalafil also received tentative FDA approval in the US, indicating its commitment to delivering high-quality treatments globally. With annual sales of approximately USD 1949.2 million for tadalafil tablets in the US, Lupin solidifies its position as a major pharmaceutical company. For more information about their partnership, visit the Lupin Pharmaceuticals collaboration page.

Apotex

Apotex is a leading producer of tadalafil, the generic equivalent of Cialis, offering high-quality and affordable medicines. In the competitive market, Apotex's tadalafil tablets are bioequivalent to Cialis, available in a 20MG strength and packaged in 30-tablet bottles. Apotex's product is part of the phosphodiesterase inhibitors therapeutic class and is administered orally. The company's efforts in introducing quality medicines have been notable, especially in cases where they have challenged patent validity, such as in the *Eli Lilly v Apotex* case where the Federal Court of Appeal upheld the invalidity of Lilly's tadalafil dosage form patent. For more detailed product information, visit the Apotex product page.

Aurobindo Pharma

Aurobindo Pharma is a prominent player in the pharmaceutical industry, known for its high-quality generic formulations, including those for erectile dysfunction treatments like Cialis. The company exports to over 150 countries and derives more than 90% of its revenues from international operations. In the financial year 2024, Aurobindo Pharma earned the highest share of revenue, 48%, from its U.S. drug formulations. With over 450 ANDAs filed and final approvals, Aurobindo Pharma boasts a robust product portfolio that includes affordable and accessible medications globally. The company's manufacturing facilities are approved by regulatory bodies such as the US FDA, UK MHRA, and EMA, ensuring stringent quality and safety standards. For more information, visit their official website.

Sun Pharma

Sun Pharma is a significant player in the erectile dysfunction drugs market, particularly known for its generic version of Cialis (tadalafil). However, in 2021, the company recalled over 100,000 bottles of its generic tadalafil tablets in the U.S. due to the use of an incorrect grade of the inactive ingredient crospovidone, affecting 36,786 bottles of the 20-mg tablet and 73,957 bottles of the 5-mg version. Despite this recall, Sun Pharma remains a major producer, contributing to the market growth expected to reach USD 6.1 billion by 2032 with a CAGR of 6.8%. The generic versions of Cialis are part of the broader market where retail pharmacies hold a 46% revenue share. Sun Pharma's involvement in the market highlights the competitive landscape and the need for stringent quality control. For further details, visit Fierce Pharma.

Zydus Pharmaceuticals

Zydus Pharmaceuticals is a leading producer of generic Cialis (tadalafil), with FDA approval for their 5mg, 10mg, and 20mg strengths since March 26, 2019. This approval has significantly expanded the availability of affordable tadalafil options, contributing to the growth of the erectile dysfunction drugs market. Zydus Pharmaceuticals is part of the broader Zydus Lifesciences Ltd., a company known for its strong market presence and innovative drug formulations. The global erectile dysfunction drugs market, which includes tadalafil, is projected to grow at a CAGR of 9.13% from 2025 to 2030. Zydus's generic tadalafil has helped in reducing the cost of treatment, making it more accessible to patients.

Torrent Pharmaceuticals

Torrent Pharmaceuticals is a significant player in the global pharmaceutical market, notably for its role in producing generic versions of popular drugs, including Cialis (tadalafil). As of 2020, Torrent Pharmaceuticals had a coverage of over 69% in the Indian Pharmaceutical Market, indicating its strong market presence. The company is one of the key manufacturers of generic Viagra and other erectile dysfunction drugs, contributing to the market growth with strategic initiatives and partnerships. Torrent Pharmaceuticals' financial performance has been robust, with a return on equity (ROE) of 24.15% in the year ending March 31, 2024, outperforming its 5-year average. This financial strength supports its capability to produce high-quality generic medications. For more insights into the erectile dysfunction drugs market, visit the Grand View Research website.